Pharmaceutical promotion to physicians and first amendment rights

被引：29
作者：
Kesselheim, Aaron S. [1 ,2 ]
Avorn, Jerry [1 ,2 ]
机构：
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2008年 / 358卷 / 16期
关键词：
D O I：
10.1056/NEJMsb0708920
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Legal restrictions on off-label promotion of drugs are being challenged in the courts as a violation of First Amendment protection of commercial speech." The authors argue that public health concerns make pharmaceutical promotion different from other commercial speech and that more stringent regulation should be permitted. Copyright © 2008 Massachusetts Medical Society. All rights reserved."
引用
收藏
页码：1727 / 1732
页数：6
相关论文
共 27 条
[1]  
Alexopoulos GS, 2004, J CLIN PSYCHIAT, V65, P5
[2]  
[Anonymous], 2003, PROTECTING AM HLTH F
[3]  
AVORN J, 2000, POWERFUL MED BENEFIT
[4]   Paying for drug approvals - Who's using whom? [J].
Avorn, Jerry .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (17) :1697-1700
[5]  
BERENSON A, 2005, NY TIMES 0819
[6]   Economic implications of evidence-based prescribing for hypertension - Can better care cost less? [J].
Fischer, MA ;
Avorn, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (15) :1850-1856
[7]  
Food and Drug Administration, 2005, FDA ISS PUBL HLTH AD
[8]  
*FOOD DRUG ADM, 2008, GUID IND GOOD REPR P
[9]  
Hall RF, 2007, FOOD DRUG LAW J, V62, P1
[10]   Safeguarding patient welfare: Who's in charge? [J].
Henney, Jane E. .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (04) :305-307
123